ISIN | LU0942225912 |
---|---|
Valor Number | 21612660 |
Bloomberg Global ID | |
Fund Name | Candriam Equities L Biotechnology R-Acc |
Fund Provider |
CANDRIAM
Serenity, Bloc - B, 19-21, route d'Arlon 8009 Strassen E-Mail: CH@Candriam.com Phone: + 352 2797-1 Web: https://www.candriam.com |
Fund Provider | CANDRIAM |
Representative in Switzerland |
CACEIS (Switzerland) SA Nyon Phone: +41 22 360 94 00 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund. |
Peculiarities |
Current Price * | 308.98 USD | 12.09.2025 |
---|---|---|
Previous Price * | 314.18 USD | 11.09.2025 |
52 Week High * | 314.39 USD | 09.09.2025 |
52 Week Low * | 226.85 USD | 08.04.2025 |
NAV * | 308.98 USD | 12.09.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 1,256,086,224 | |
Unit/Share Assets *** | 36,169,291 | |
Trading Information SIX |
YTD Performance | +14.04% |
31.12.2024 - 12.09.2025
31.12.2024 12.09.2025 |
---|---|---|
YTD Performance (in CHF) | +0.08% |
31.12.2024 - 12.09.2025
31.12.2024 12.09.2025 |
1 month | +8.97% |
12.08.2025 - 12.09.2025
12.08.2025 12.09.2025 |
3 months | +15.97% |
12.06.2025 - 12.09.2025
12.06.2025 12.09.2025 |
6 months | +14.12% |
12.03.2025 - 12.09.2025
12.03.2025 12.09.2025 |
1 year | +4.32% |
12.09.2024 - 12.09.2025
12.09.2024 12.09.2025 |
2 years | +28.11% |
12.09.2023 - 12.09.2025
12.09.2023 12.09.2025 |
3 years | +30.37% |
12.09.2022 - 12.09.2025
12.09.2022 12.09.2025 |
5 years | +37.81% |
14.09.2020 - 12.09.2025
14.09.2020 12.09.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Alnylam Pharmaceuticals Inc | 6.35% | |
---|---|---|
Vertex Pharmaceuticals Inc | 5.40% | |
Amgen Inc | 5.32% | |
Gilead Sciences Inc | 5.09% | |
Regeneron Pharmaceuticals Inc | 3.98% | |
BeOne Medicines Ltd ADR | 3.32% | |
Insmed Inc | 3.14% | |
Neurocrine Biosciences Inc | 2.81% | |
BioNTech SE ADR | 2.71% | |
Ascendis Pharma AS ADR | 2.46% | |
Last data update | 31.07.2025 |
TER | |
---|---|
TER date | |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.11% |
SRRI ***
|
|
SRRI date *** | 31.08.2025 |